United Therapeutics - UTHR Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 2 sell ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" UTHR shares.
View UTHR analyst ratings or view top-rated stocks.

10 brokerages have issued twelve-month price objectives for United Therapeutics' stock. Their UTHR share price forecasts range from $230.00 to $375.00. On average, they predict the company's stock price to reach $291.55 in the next twelve months. This suggests a possible upside of 30.2% from the stock's current price.
View analysts price targets for UTHR or view top-rated stocks among Wall Street analysts.

United Therapeutics' stock was trading at $278.09 at the start of the year. Since then, UTHR stock has decreased by 19.5% and is now trading at $223.96.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our UTHR earnings forecast.

United Therapeutics Co. (NASDAQ:UTHR) posted its quarterly earnings data on Wednesday, February, 22nd. The biotechnology company reported $2.67 earnings per share for the quarter, missing the consensus estimate of $4.12 by $1.45. The biotechnology company had revenue of $491.50 million for the quarter, compared to analyst estimates of $519.20 million. United Therapeutics had a net margin of 37.56% and a trailing twelve-month return on equity of 16.30%. The business's quarterly revenue was up 18.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.35 EPS.

ETFs with the largest weight of United Therapeutics (NASDAQ:UTHR) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), First Trust Nasdaq Pharmaceuticals ETF (FTXH), First Trust US Equity Opportunities ETF (FPX), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Dynamic Pharmaceuticals ETF (PJP), The Acquirers Fund (ZIG), AdvisorShares Dorsey Wright Alpha Equal Weight ETF (DWEQ) and Invesco DWA Healthcare Momentum ETF (PTH).

64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of UTHR stock can currently be purchased for approximately $223.96.

United Therapeutics (NASDAQ:UTHR) has a market capitalization of $10.37 billion and generates $1.94 billion in revenue each year. The biotechnology company earns $727.30 million in net income (profit) each year or $15.02 on an earnings per share basis.

The company employs 965 workers across the globe.

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The official website for the company is www.unither.com. The biotechnology company can be reached via phone at (301) 608-9292, via email at ir@unither.com, or via fax at 301-608-9291.